GlobeNewswire: LogicBio Therapeutics Contains the last 10 of 41 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T10:27:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/12/2126032/0/en/LogicBio-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics to Present at Upcoming Investor Conferences2020-11-12T21:05:00Z<![CDATA[LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today announced senior member of management will be presenting at upcoming investor conferences]]>https://www.globenewswire.com/news-release/2020/11/09/2122530/0/en/LogicBio-Therapeutics-Reports-Third-Quarter-2020-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update2020-11-09T11:30:00Z<![CDATA[- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021- Fast Track designation for LB-001 in MMA received in November 2020- First follow-on offering post-IPO closed in October 2020]]>https://www.globenewswire.com/news-release/2020/11/04/2120037/0/en/LogicBio-Therapeutics-Receives-FDA-Fast-Track-Designation-for-LB-001-for-the-Treatment-of-Methylmalonic-Acidemia-MMA.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA) 2020-11-04T12:45:00Z<![CDATA[Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients]]>https://www.globenewswire.com/news-release/2020/11/03/2119611/0/en/LogicBio-Therapeutics-Announces-Appointment-of-Veteran-Biotech-Executive-Mariana-Nacht-Ph-D-as-Chief-Scientific-Officer-and-Kyle-Chiang-Ph-D-Promoted-to-Chief-Operating-Officer.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer2020-11-03T21:05:00Z<![CDATA[LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the appointment of Mariana Nacht, Ph.D., as chief scientific officer, effective Nov. 30, 2020, and the promotion of Kyle Chiang, Ph.D., to chief operating officer, effective Nov. 2, 2020.]]>https://www.globenewswire.com/news-release/2020/10/05/2103693/0/en/LogicBio-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares2020-10-05T15:12:28Z<![CDATA[LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of common stock at a price to the public of $6.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares of common stock. The gross proceeds to LogicBio from the offering were $48.3 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio.]]>https://www.globenewswire.com/news-release/2020/10/01/2102289/0/en/LogicBio-Therapeutics-Announces-Pricing-of-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock2020-10-01T13:10:15Z<![CDATA[LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of common stock at a price to the public of $6.00 per share. Gross proceeds to LogicBio from the offering are expected to be $42.0 million, before deducting underwriting discounts and commissions and offering expenses payable by LogicBio. In addition, LogicBio has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock, at the public offering price less underwriting discounts and commissions. All shares are being sold by LogicBio. The offering is expected to close on October 5, 2020, subject to the satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2020/09/30/2101707/0/en/LogicBio-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Announces Proposed Public Offering of Common Stock2020-09-30T20:01:00Z<![CDATA[LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of the offering, LogicBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. All shares being offered are to be sold by LogicBio.]]>https://www.globenewswire.com/news-release/2020/09/25/2099519/0/en/LogicBio-Therapeutics-to-Present-at-the-Jefferies-Virtual-Gene-Editing-Therapy-Summit-October-2-2020.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics to Present at the Jefferies Virtual Gene Editing/Therapy Summit October 2, 20202020-09-25T23:49:04Z<![CDATA[LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on Friday, October 2, 2020 at 11:30 AM, ET.]]>https://www.globenewswire.com/news-release/2020/09/25/2099518/0/en/LogicBio-Therapeutics-to-Present-at-the-4th-Annual-Chardan-Virtual-Genetic-Medicines-Conference-October-5-2020.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 20202020-09-25T23:47:43Z<![CDATA[LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on Monday, October 5, 2020 at 11 AM, ET.]]>https://www.globenewswire.com/news-release/2020/08/10/2075471/0/en/LogicBio-Therapeutics-Announces-SUNRISE-Phase-1-2-Clinical-Design-for-LB-001-for-the-Treatment-of-Methylmalonic-Acidemia-in-Pediatric-Patients.html?f=22&fvtc=4&fvtv=51193LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients2020-08-10T10:35:00Z<![CDATA[– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –]]>